Intelligence · Clinical Development
Pipeline search results
Programs matching “chemotherapy” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 127 pipeline programs matching "chemotherapy" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Immunotherapy combined with chemotherapy
The First People's Hospital of Lianyungang
Rectal Adenocarcinoma
1 trial -
Ivonescimab Combined With Chemotherapy
The First People's Hospital of Lianyungang
Pretreated Pleural Mesothelioma
1 trial -
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
The George Institute
Colon cancer
1 trial -
Neoadjuvant Chemotherapy
Xiangya Hospital of Central South University
High-Grade Upper Tract Urothelial Carcinoma
1 trial -
Neoadjuvant Chemotherapy (NACT)
The First People's Hospital of Lianyungang
HR+/HER2- Breast Cancer
1 trial -
Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer (NSCLC)
1 trial -
PASSION
Verona Pharma Ireland Limited
Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy
1 trial -
PD-1 Inhibitor plus Chemotherapy
Sichuan University
Esophageal Squamous Cell Carcinoma
1 trial -
Palmidrol
United Therapeutics Europe Ltd
Chemotherapy-Induced Peripheral Neuropathy
1 trial -
Pre-operative chemotherapy
Nanjing Zenshine Pharmaceuticals
Gastric Cancers
1 trial -
Pre-operative chemotherapy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Romiplostim N01
Hospital Authority, Hong Kong
Chemotherapy-induced Thrombocytopenia
1 trial -
SCHLC007
Shanghai Chest Hospital
NSCLC
1 trial -
SOX Chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastroesophageal Junction Adenocarcinoma
1 trial -
SSS06
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Chemotherapy-induced Anemia
1 trial -
Sintilimab Combined with Platinum-containing Chemotherapy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Systemic chemotherapy (FOLFIRI)
The First People's Hospital of Lianyungang
Rectum Cancer
1 trial -
TEMOZOLOMIDE , IRINOTECAN
Fondazione Telethon ETS
Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy
1 trial -
TPC induction chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
Tislelizumab combined with chemotherapy
The First People's Hospital of Lianyungang
Rectal Cancer
1 trial -
Toripalimab + Chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thymic Epithelial Tumor
1 trial -
Toripalimab + Chemotherapy
Coherus Oncology
Head and Neck Cancer
1 trial -
UC-0110/1719
Ningbo Cancer Hospital
Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.